CLAIMS

1.- A compound of general formula I:

10 where:

5

 R_1 is selected from the group formed by H, $-(CH_2)_3-$, $-(CH_2)_4-$, $-CH_2-S-CH_2$, $-S-CH_2-CH_2-$;

 R_2 is selected from the group formed by N, S;


n has a value of 0 or 1;

Z is selected from the group formed by C2-C10-alkyl, C2-C10-alkenyl, C2-C10-alkinyl;

 R_3 is selected from the group formed by H, C1-C10-alkyl, aryl, aralkyl;

m has a value of 0 to 2;

 R_4 is selected from the group formed by O, CH_2 ; R_5 is selected from the group formed by:



where:

 R_6 is selected from the group formed by H, C1-C5-alkyl, C1-C5-alkoxyl, OH, F, Cl, Br, I;

X is selected from the group formed by O, S, NH, NCH_3 ;

- Y is selected from the group formed by O, NH;
 W is selected from the group formed by S, NH;
 and their salts and solvates.
- 2. A compound according to claim 1, characterized in that Z represents a C2-C10-alkyl group and R_5 is selected from the group formed by:

15

where:

- 20 R_6 is selected from the group formed by H, C1-C5-alkyl, C1-C5-alkoxyl, OH, F, Cl, Br, I.
 - 3. A compound according to any of claims 1 to $\frac{3}{2}$, characterized in that Z is butyl, R_3 is H and R_5 is selected from the group formed by:

25

30 where:

 R_6 is selected from the group formed by H, C1-C5-alkyl, C1-C5-alkoxyl, OH, F, C1, Br, I.

4. A process to prepare a compound according to any one of claims 1 to 3, characterized in that:

(A) the intermediate halogen derivatives II are made to react, where L means Cl, Br, with amines III in acetonitrile, according to the scheme of reaction I:

Scheme I

5

10

15

(B) the intermediate amines IV are made to react with suitable halogen derivatives V, where L means Cl, Br, in acetonitrile, according to the scheme of reaction II:

Scheme II

where the definitions of R_1 , R_2 , n, Z, m, R_4 and R_5 in these schemes are identical to those previously made for the products of the invention.

- 5. Process according to claim 4, characterized in that those compounds with R_3 different from H are obtained by alkylation of the analogues wherein R_3 is hydrogen.
- 6. Pharmaceutical composition characterized in that it comprises a therapeutically effective quantity of any of the compounds defined in the preceding claims 1 to 3 together with a pharmaceutically acceptable carrier or excipient.
- 7. Use of a compound according to any of the preceding claims 1 to 3, for the production of a medicine for the treatment and/or prevention of pathological states

wherein the $5-\mathrm{HT}_{1A}$ receptor agonists are indicated.

5

8. Use of a compound according to any of the preceding claims 1 to 3, for the production of a medicine for the treatment and/or prophylaxis of cerebral damage produced by thromboembolic stroke or cranium-brain traumatic injuries.